DB
PACB icon

Dmitry Balyasny’s Pacific Biosciences PACB Stock Holding History

Dmitry Balyasny’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$948K Buy
564,339
+303,801
+117% +$442K ﹤0.01% 2245
2026
Q1 		$344K Buy
+260,538
New +$466K ﹤0.01% 2511
2024
Q2 		– Sell
-288,612
Closed -$1.08M – 2967
2024
Q1 		$1.08M Buy
+288,612
New +$1.69M ﹤0.01% 1751
2023
Q4 		– Sell
-326,770
Closed -$2.73M – 2794
2023
Q3 		$2.73M Buy
+326,770
New +$3.73M 0.01% 1291
2023
Q1 		– Sell
-349,391
Closed -$2.86M – 3018
2022
Q4 		$2.86M Buy
+349,391
New +$3.01M 0.01% 1261
2022
Q1 		– Sell
-26,309
Closed -$538K – 2750
2021
Q4 		$538K Buy
+26,309
New +$635K ﹤0.01% 1604
2020
Q3 		– Sell
-19,029
Closed -$66K – 1513
2020
Q2 		$66K Buy
+19,029
New +$64.8K ﹤0.01% 1067
2019
Q4 		– Sell
-651,043
Closed -$3.36M – 1399
2019
Q3 		$3.36M Sell
651,043
-38,237
-6% -$214K 0.02% 625
2019
Q2 		$4.17M Sell
689,280
-749,776
-52% -$5.26M 0.03% 664
2019
Q1 		$10.4M Buy
1,439,056
+1,402,467
+3,833% +$10.1M 0.07% 371
2018
Q4 		$271K Sell
36,589
-436,767
-92% -$2.77M ﹤0.01% 1247
2018
Q3 		$2.56M Buy
+473,356
New +$2.03M 0.01% 907
2018
Q2 		– Sell
-19,958
Closed -$41K – 2056
2018
Q1 		$41K Buy
19,958
+662
+3% +$1.72K ﹤0.01% 1867
2017
Q4 		$51K Sell
19,296
-14,204
-42% -$49.7K ﹤0.01% 2011
2017
Q3 		$176K Buy
+33,500
New +$144K ﹤0.01% 1724
2016
Q2 		– Sell
-11,100
Closed -$94K – 1372
2016
Q1 		$94K Sell
11,100
-244,556
-96% -$2.41M ﹤0.01% 1205
2015
Q4 		$3.36M Buy
+255,656
New +$2.29M 0.02% 574

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dmitry Balyasny's PACB Position: Q2 2026 in Review

Dmitry Balyasny increased its Pacific Biosciences (PACB) stake by 117% in Q2 2026, buying an estimated $442K and bringing the position to 564,339 shares worth $948K. The position accounts for ﹤0.01% of the portfolio, ranked #2245.

Dmitry Balyasny first reported a position in PACB in Q4 2015 and has held it in 17 quarters since. The position peaked at $10.4M in Q1 2019. 222 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Dmitry Balyasny held 564,339 shares of Pacific Biosciences worth $948K as of Q2 2026.
  • Dmitry Balyasny bought 303,801 Pacific Biosciences shares in Q2 2026, an estimated $442K.
  • Pacific Biosciences made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2245 holding.
  • Dmitry Balyasny first reported a position in Pacific Biosciences in Q4 2015 and has held it in 17 quarters since.
  • Dmitry Balyasny's Pacific Biosciences position peaked at $10.4M in Q1 2019.
  • 222 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.